ALGS Relative Valuation
ALGS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALGS is overvalued; if below, it's undervalued.
Historical Valuation
Aligos Therapeutics Inc (ALGS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.07. The fair price of Aligos Therapeutics Inc (ALGS) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：10.09
Fair
-1.29
PE
1Y
3Y
5Y
Trailing
Forward
0.31
EV/EBITDA
Aligos Therapeutics Inc. (ALGS) has a current EV/EBITDA of 0.31. The 5-year average EV/EBITDA is -3.80. The thresholds are as follows: Strongly Undervalued below -18.91, Undervalued between -18.91 and -11.35, Fairly Valued between 3.76 and -11.35, Overvalued between 3.76 and 11.32, and Strongly Overvalued above 11.32. The current Forward EV/EBITDA of 0.31 falls within the Historic Trend Line -Fairly Valued range.
0.33
EV/EBIT
Aligos Therapeutics Inc. (ALGS) has a current EV/EBIT of 0.33. The 5-year average EV/EBIT is -3.76. The thresholds are as follows: Strongly Undervalued below -18.84, Undervalued between -18.84 and -11.30, Fairly Valued between 3.78 and -11.30, Overvalued between 3.78 and 11.31, and Strongly Overvalued above 11.31. The current Forward EV/EBIT of 0.33 falls within the Historic Trend Line -Fairly Valued range.
47.95
PS
Aligos Therapeutics Inc. (ALGS) has a current PS of 47.95. The 5-year average PS is 64.14. The thresholds are as follows: Strongly Undervalued below -256.59, Undervalued between -256.59 and -96.23, Fairly Valued between 224.51 and -96.23, Overvalued between 224.51 and 384.87, and Strongly Overvalued above 384.87. The current Forward PS of 47.95 falls within the Historic Trend Line -Fairly Valued range.
-0.67
P/OCF
Aligos Therapeutics Inc. (ALGS) has a current P/OCF of -0.67. The 5-year average P/OCF is -5.28. The thresholds are as follows: Strongly Undervalued below -22.82, Undervalued between -22.82 and -14.05, Fairly Valued between 3.49 and -14.05, Overvalued between 3.49 and 12.26, and Strongly Overvalued above 12.26. The current Forward P/OCF of -0.67 falls within the Historic Trend Line -Fairly Valued range.
-0.64
P/FCF
Aligos Therapeutics Inc. (ALGS) has a current P/FCF of -0.64. The 5-year average P/FCF is -5.83. The thresholds are as follows: Strongly Undervalued below -27.36, Undervalued between -27.36 and -16.59, Fairly Valued between 4.94 and -16.59, Overvalued between 4.94 and 15.70, and Strongly Overvalued above 15.70. The current Forward P/FCF of -0.64 falls within the Historic Trend Line -Fairly Valued range.
Aligos Therapeutics Inc (ALGS) has a current Price-to-Book (P/B) ratio of 0.86. Compared to its 3-year average P/B ratio of 1.14 , the current P/B ratio is approximately -24.44% higher. Relative to its 5-year average P/B ratio of 2.57, the current P/B ratio is about -66.42% higher. Aligos Therapeutics Inc (ALGS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -104.03%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -74.90% , the current FCF yield is about -100.00% lower.
0.86
P/B
Median3y
1.14
Median5y
2.57
-130.95
FCF Yield
Median3y
-104.03
Median5y
-74.90
Competitors Valuation Multiple
The average P/S ratio for ALGS's competitors is 0.00, providing a benchmark for relative valuation. Aligos Therapeutics Inc Corp (ALGS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -41.61%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ALGS decreased by 74.67% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.52K to -4.26K.
The secondary factor is the Revenue Growth, contributed -41.61%to the performance.
Overall, the performance of ALGS in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Aligos Therapeutics Inc (ALGS) currently overvalued or undervalued?
What is Aligos Therapeutics Inc (ALGS) fair value?
How does ALGS's valuation metrics compare to the industry average?
What is the current P/B ratio for Aligos Therapeutics Inc (ALGS) as of Dec 05 2025?
What is the current FCF Yield for Aligos Therapeutics Inc (ALGS) as of Dec 05 2025?
What is the current Forward P/E ratio for Aligos Therapeutics Inc (ALGS) as of Dec 05 2025?